A series of executive orders from US President Donald Trump has created anxiety among patent practitioners who fear ...

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Adam Fowles, Dirk Bernhardt and Brett Bostrom of Haynes Boone discuss preparing a revival petition for patents or ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...

Artificial Intelligence (AI) in intellectual property is as big – and as fast-changing – a topic as ever. On January 14, 2025 ...

The first day of IPWatchdog’s PTAB Masters 2025 wrapped up with a session in which three IP luminaries weighed in on the ...

The U.S. Patent and Trademark Office (USPTO) debuted its 2025 Artificial Intelligence Strategy (AI Strategy) policy on Jan.

The agency said improvements in generative AI could enable systems to “play a greater role in the inventive process, potentially even contributing in ways that resemble human inventors,” which USPTO ...

Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application ...